The benefits of innovation have been reserved in the main for a subset of wealthy countries so in response, Novartis AG has reframed its definition of business success to the impact that its drugs have globally, moving beyond a purely transactional approach and looking holistically into the real barriers to access to medicines in the poorer parts of the world.
Novartis Measures Malaria Success On Impact Rather Than Money
The Swiss major’s global health chief Lutz Hegemann tells Scrip on a trip to Rwanda that being a profitable enterprise while helping to improve access to new and older therapies for those who need it most is the real measure of a successful business.
